Abstract
Molecular pathological epidemiology (MPE) is a transdisciplinary and relatively new scientific discipline that integrates theory, methods, and resources from epidemiology, pathology, biostatistics, bioinformatics, and computational biology. The underlying objective of MPE research is to better understand the etiology and progression of complex and heterogeneous human diseases with the goal of informing prevention and treatment efforts in population health and clinical medicine. Although MPE research has been commonly applied to investigating breast, lung, and colorectal cancers, its methodology can be used to study most diseases. Recent successes in MPE studies include: (1) the development of new statistical methods to address etiologic heterogeneity; (2) the enhancement of causal inference; (3) the identification of previously unknown exposure-subtype disease associations; and (4) better understanding of the role of lifestyle/behavioral factors on modifying prognosis according to disease subtype. Central challenges to MPE include the relative lack of transdisciplinary experts, educational programs, and forums to discuss issues related to the advancement of the field. To address these challenges, highlight recent successes in the field, and identify new opportunities, a series of MPE meetings have been held at the Dana–Farber Cancer Institute in Boston, MA. Herein, we share the proceedings of the Third International MPE Meeting, held in May 2016 and attended by 150 scientists from 17 countries. Special topics included integration of MPE with immunology and health disparity research. This meeting series will continue to provide an impetus to foster further transdisciplinary integration of divergent scientific fields.
Similar content being viewed by others
References
Ogino S, Stampfer M (2010) Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102:365–367
Ogino S, Lochhead P, Chan AT et al (2013) Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 26:465–484
Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S (2015) Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med 48:116–119
Nishi A, Milner DA Jr, Giovannucci EL et al (2016) Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn 16:11–23
Ogino S, Chan AT, Fuchs CS, Giovannucci E (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60:397–411
Ogino S, Nishihara R, VanderWeele TJ et al (2016) Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 27:602–611
Curtin K, Slattery ML, Samowitz WS. (2011) CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int, pp 902674.
Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R (2014) Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 20:6055–6072
Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L (2016) Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 1866:163–176
Kuipers EJ, Grady WM, Lieberman D, et al. (2015) Colorectal cancer. Nat Rev Dis Primers. 1:15065.
Martinez-Useros J, Garcia-Foncillas J (2016) Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med 14:21
Kuroiwa-Trzmielina J, Wang F, Rapkins RW et al (2016) SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer. Clin Cancer Res 22:6266–6277
Chia WK, Ali R, Toh HC (2012) Aspirin as adjuvant therapy for colorectal cancer–reinterpreting paradigms. Nat Rev Clin Oncol 9:561–570
Hughes LA, Khalid-de Bakker CA, Smits KM, et al. (2012) The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 1825: 77–85.
Buchanan DD, Win AK, Walsh MD et al (2013) Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev 22:917–926
Figueiredo JC, Lewinger JP, Song C et al (2011) Genotype-environment interactions in microsatellite stable/microsatellite instability-low colorectal cancer: results from a genome-wide association study. Cancer Epidemiol Biomark Prev 20:758–766
Lee PN, Forey BA, Coombs KJ (2012) Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 12:385
Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P (2008) Smoking and colorectal cancer: a meta-analysis. JAMA 300:2765–2778
Secretan B, Straif K, Baan R et al (2009) A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 10:1033–1034
Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113–130
Poynter JN, Haile RW, Siegmund KD et al (2009) Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomark Prev 18:2745–2750
Slattery ML, Curtin K, Anderson K et al (2000) Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 92:1831–1836
Limsui D, Vierkant RA, Tillmans LS et al (2010) Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 102:1012–1022
Nishihara R, Morikawa T, Kuchiba A et al (2013) A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 178:84–100
Ogino S, Campbell PT, Nishihara R et al (2015) Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 26:959–972
Curtin K, Samowitz WS, Ulrich CM et al (2011) Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer 63:357–366
The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337
Giannakis M, Hodis E, Jasmine Mu X et al (2014) RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 46:1264–1266
Giannakis M, Mu XJ, Shukla SA et al (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15:857–865
Howie B, Sherwood AM, Berkebile AD et al (2015) High-throughput pairing of T cell receptor alpha and beta sequences. Sci Transl Med 7:301ra131
Masugi Y, Nishihara R, Yang J et al (2016) Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (in press)
Mima K, Nishihara R, Nowak JA et al (2016) MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer. Immunol Res 4:33–40
Mima K, Sukawa Y, Nishihara R et al (2015) Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 1:653–661
Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8:711–719
Song M, Nishihara R, Wang M et al (2016) Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut 65:296–304
Hanyuda A, Ogino S, Qian ZR et al (2016) Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer 139:854–868
Song M, Nishihara R, Cao Y et al (2016) Marine omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer characterized by tumor-infiltrating T cells. JAMA Oncol 2:1197–1206
Tan DS, Mok TS, Rebbeck TR (2016) Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin Oncol 34:91–101
Almendro V, Cheng YK, Randles A, et al. (2014) Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 6:514–527.
Almendro V, Kim HJ, Cheng YK et al (2014) Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74:1338–1348
Janiszewska M, Liu L, Almendro V et al (2015) In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet 47:1212–1219
Bogdanov AA Jr, Dixon AJ, Gupta S et al (2016) Synthesis and testing of modular dual-modality nanoparticles for magnetic resonance and multispectral photoacoustic imaging. Bioconjug Chem 27:383–390
Begg CB, Orlow I, Zabor EC, et al. (2015) Identifying etiologically distinct sub-types of cancer: a demonstration project involving breast cancer. Cancer Med 4:1432–1439.
VanderWeele TJ, Robins JM (2007) The identification of synergism in the sufficient-component-cause framework. Epidemiology 18:329–339
VanderWeele TJ (2009) Sufficient cause interactions and statistical interactions. Epidemiology 20:6–13
Vanderweele TJ (2010) Sufficient cause interactions for categorical and ordinal exposures with three levels. Biometrika 97:647–659
Glass K, Quackenbush J, Spentzos D, Haibe-Kains B, Yuan GC (2015) A network model for angiogenesis in ovarian cancer. BMC Bioinform 16:115
Jaffe AE, Irizarry RA (2014) Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol 15:R31
Huttenhower C, Knight R, Brown CT et al (2014) Advancing the microbiome research community. Cell 159:227–230
Dubin N, Pasternack BS (1986) Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol 123:1101–1117
Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE (2013) A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med 32:5039–5052
Chatterjee N, Sinha S, Diver WR, Feigelson HS (2010) Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika 97:683–698
Wang M, Kuchiba A, Ogino S (2015) A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol 182:263–270
Rosner B, Glynn RJ, Tamimi RM et al (2013) Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol 178:296–308
Schildkraut JM, Iversen ES, Akushevich L et al (2013) Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomark Prev 22:1709–1721
Nevo D, Zucker DM, Tamimi RM, Wang M (2016) Accounting for measurement error in biomarker data and misclassification of subtypes in the analysis of tumor data. Stat Med 35:5686–5700
Wang M, Spiegelman D, Kuchiba A et al (2016) Statistical methods for studying disease subtype heterogeneity. Stat Med 35:782–800
The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
Dorman SN, Baranova K, Knoll JH et al (2016) Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. Mol Oncol 10:85–100
Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649–658
Reimers MS, Bastiaannet E, Langley RE, et al. (2014) Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 174:732–739.
Domingo E, Church DN, Sieber O et al (2013) Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 31:4297–4305
Cao Y, Nishihara R, Qian ZR et al (2016) Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 151:879–892
Campbell PT, Deka A, Briggs P et al (2014) Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomark Prev 23:2694–2702
Campbell PT, Jacobs ET, Ulrich CM et al (2010) Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 102:391–400
Campbell PT, Newton CC, Newcomb PA et al (2015) Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomark Prev 24:1229–1238
Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomark Prev 16:2331–2343
Phipps AI, Ahnen DJ, Campbell PT et al (2014) Family history of colorectal cancer is not associated with colorectal cancer survival regardless of microsatellite instability status. Cancer Epidemiol Biomark Prev 23:1700–1704
Acknowledgments
Grant support: NIH R13 CA203287 (to S.O.: supported by the National Cancer Institute, National Human Genome Research Institute, and National Institute of Environmental Health Sciences). R35 CA197735 (to S.O.). P30 CA006516 (Dana–Farber Harvard Cancer Center Support Grant; to E.J. Benz;). Nodal Award (to S.O.) from Dana–Farber Harvard Cancer Center.
Author information
Authors and Affiliations
Corresponding authors
Additional information
P. T. Campbell and S. Ogino contributed equally to this work.
Rights and permissions
About this article
Cite this article
Campbell, P.T., Rebbeck, T.R., Nishihara, R. et al. Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 28, 167–176 (2017). https://doi.org/10.1007/s10552-016-0845-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-016-0845-z